Palvella Therapeutics (PVLA) announced the successful completion of TOIVA, a Phase 2 trial of QTORIN 3.9% rapamycin anhydrous gel for the treatment of cutaneous venous malformations. The Phase 2 trial enrolled 16 subjects at leading vascular anomaly centers, meeting the original recruitment target of approximately 15 subjects. Top-line results from TOIVA are expected in mid-December 2025.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on PVLA:
- Palvella Therapeutics initiated with an Outperform at Oppenheimer
- Palvella Therapeutics Accelerates U.S. Launch Planning
- Palvella Therapeutics appoints Osborne as Chief Innovation Officer
- Palvella Therapeutics price target raised to $66 from $52 at Canaccord
- Palvella Therapeutics price target raised to $75 from $38 at H.C. Wainwright